Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.46 |
| ▸ | VHL | P40337 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145755 | 0.89 | KMT2A (0.56) | KMT2AHDAC1HDAC6MAPTALDH1A1 | |
| SCHEMBL12133623 | 0.84 | KMT2A (0.76) | KMT2AHDAC1HDAC6MAPTALDH1A1 | |
| SCHEMBL15947376 | 0.81 | KMT2A (0.66) | KMT2AHDAC1HDAC6MAPTALDH1A1 | |
| SCHEMBL667359 | 0.80 | KDM4E (0.65) | HDAC1HDAC6MAPTALDH1A1HDAC3 | |
| SCHEMBL6615627 | 0.80 | TSHR (0.54) | KMT2AHDAC1MAPTALDH1A1RAB9A | |
| SCHEMBL6465799 | 0.79 | CYP2C9 (0.60) | KMT2APOLBGAA | |
| SCHEMBL5147671 | 0.79 | MEN1 (0.48) | KMT2AHDAC1HDAC6MAPTALDH1A1 | |
| SCHEMBL1355160 | 0.79 | ERCC1 (0.56) | KMT2AHDAC1MAPTALDH1A1 | |
| SCHEMBL7406842 | 0.79 | KMT2A (0.49) | KMT2AHDAC1HDAC6MAPTALDH1A1 | |
| SCHEMBL97001 | 0.78 | KMT2A (0.68) | KMT2AHDAC1HDAC6MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | claimed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | claimed |
| EP-3692023-B1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST BIOTHERAPEUTICS INC (KR) | 2023-05-17 | — | — | EP | claimed |
| EP-3927706-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| EP-3927705-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | claimed |
| CN-113454082-A | Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases | 第一生物治疗股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-113454081-A | Imidazopyridinyl compounds and their use for the treatment of proliferative diseases | 第一生物治疗股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2021-04-06 | — | — | US | claimed |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | claimed |
| EP-1131291-B1 | 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | claimed |
| US-6342509-B1 | ANTIASTHMATICS, ANTIHISTAMINES OR BRONCHODIALATORS | SYNTEX (U.S.A.) LLC | 2002-01-29 | — | — | US | claimed |
| CN-1326440-A | Piperdine CCR-3 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-12-12 | — | — | CN | claimed |
| EP-1131291-A1 | 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | claimed |
| EP-1131290-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | claimed |
| US-6140344-A | FOR TREATING PATHOLOGICAL CONDITIONS SUCH AS ASTHMA, RHINITIS, ECZEMA AND PARASITIC INFECTIONS FEATURING TISSUE EOSINOPHILIA | SYNTEX (U.S.A.) INC. (US) | 2000-10-31 | — | — | US | claimed |
| WO-2000031033-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | claimed |
| WO-2000029377-A1 | 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | KMT2A 2106/4885HDAC1 417/4885HDAC6 22/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | KMT2A 2106/4885HDAC1 417/4885HDAC6 22/4885 |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | ABL2, ABL1, MAPT | KMT2A 1087/4885HDAC1 964/4885HDAC6 64/4885 |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | KMT2A 2106/4885HDAC1 417/4885HDAC6 22/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | KMT2A 3435/4885HDAC1 1096/4885HDAC6 1419/4885 |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | KMT2A 1087/4885HDAC1 964/4885HDAC6 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.